非转移性-话题@MedSci

#非转移性#

40篇内容 | 722人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2080176, encodeId=d87020801e66f, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估, objectType=article, longId=735694, objectId=74d3e3569400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d3e3569400, replyNumber=0, likeNumber=52, createdTime=2023-04-03, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d3e3569400, moduleTitle=Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d3e3569400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080175, encodeId=d9ea20801e5d8, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估, objectType=article, longId=731928, objectId=fea2e3192803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fea2e3192803, replyNumber=0, likeNumber=53, createdTime=2022-08-19, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fea2e3192803, moduleTitle=Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fea2e3192803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080174, encodeId=418c20801e4bb, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Eur Urol：非转移性前列腺癌患者中，高强度聚焦超声局部治疗后的癌症控制结果 , objectType=article, longId=299087, objectId=d12e29908ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d12e29908ecd, replyNumber=0, likeNumber=56, createdTime=2022-12-08, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d12e29908ecd, moduleTitle=Eur Urol：非转移性前列腺癌患者中，高强度聚焦超声局部治疗后的癌症控制结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d12e29908ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080173, encodeId=19b620801e3b1, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异, objectType=article, longId=293862, objectId=e5bc2938625c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5bc2938625c, replyNumber=0, likeNumber=32, createdTime=2022-02-10, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5bc2938625c, moduleTitle=Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5bc2938625c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080172, encodeId=07b620801e224, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=BMC Cancer：随访长达10年的前瞻性研究证实女性非转移性乳腺癌患者越年轻预后越差, objectType=article, longId=293652, objectId=f033293652ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f033293652ef, replyNumber=0, likeNumber=38, createdTime=2022-03-19, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f033293652ef, moduleTitle=BMC Cancer：随访长达10年的前瞻性研究证实女性非转移性乳腺癌患者越年轻预后越差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f033293652ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080166, encodeId=6ad72080166ff, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Eur Urol Focus：非转移性前列腺癌根治术后尿失禁的患者和肿瘤相关预后因素分析 , objectType=article, longId=211755, objectId=1f0d211e555f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f0d211e555f, replyNumber=0, likeNumber=48, createdTime=2021-06-20, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f0d211e555f, moduleTitle=Eur Urol Focus：非转移性前列腺癌根治术后尿失禁的患者和肿瘤相关预后因素分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f0d211e555f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080171, encodeId=2aaa20801e1db, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, objectType=article, longId=218769, objectId=9c2d218e69ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2d218e69ce, replyNumber=0, likeNumber=31, createdTime=2022-05-26, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2d218e69ce, moduleTitle=J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c2d218e69ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080164, encodeId=9de72080164c8, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Prostate Cancer P D：非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较：倾向性评分匹配研究, objectType=article, longId=206746, objectId=ac1a206e46c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac1a206e46c9, replyNumber=0, likeNumber=48, createdTime=2021-09-14, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac1a206e46c9, moduleTitle=Prostate Cancer P D：非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较：倾向性评分匹配研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac1a206e46c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080170, encodeId=5efb20801e07f, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Int J Urol：非转移性pT3a肾细胞癌的术后复发预测因素调查 , objectType=article, longId=216723, objectId=55de216e2336, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55de216e2336, replyNumber=0, likeNumber=51, createdTime=2021-12-22, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55de216e2336, moduleTitle=Int J Urol：非转移性pT3a肾细胞癌的术后复发预测因素调查 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55de216e2336)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080165, encodeId=d75a20801655a, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析, objectType=article, longId=207265, objectId=388d20e265f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=388d20e265f5, replyNumber=0, likeNumber=38, createdTime=2021-10-31, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=388d20e265f5, moduleTitle=ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=388d20e265f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080167, encodeId=1e16208016e0e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=J Clin Oncol：放疗(RT)和雄激素剥夺疗法(ADT)联合或不联合多西他赛治疗非转移性的不良风险前列腺癌的疗效:一项前瞻性随机研究, objectType=article, longId=213679, objectId=ac592136e99d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac592136e99d, replyNumber=0, likeNumber=28, createdTime=2022-06-01, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac592136e99d, moduleTitle=J Clin Oncol：放疗(RT)和雄激素剥夺疗法(ADT)联合或不联合多西他赛治疗非转移性的不良风险前列腺癌的疗效:一项前瞻性随机研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac592136e99d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080169, encodeId=c0a9208016994, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, objectType=article, longId=215209, objectId=93d5215209e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93d5215209e6, replyNumber=0, likeNumber=38, createdTime=2021-08-10, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93d5215209e6, moduleTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93d5215209e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080168, encodeId=9a80208016890, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, objectType=article, longId=215061, objectId=7b66215061fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b66215061fc, replyNumber=0, likeNumber=41, createdTime=2021-11-28, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b66215061fc, moduleTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b66215061fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080160, encodeId=d5b820801600e, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, objectType=article, longId=200507, objectId=259720050e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259720050e88, replyNumber=0, likeNumber=40, createdTime=2020-09-15, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259720050e88, moduleTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=259720050e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080162, encodeId=198c2080162d9, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统, objectType=article, longId=202517, objectId=e79120251eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79120251eaf, replyNumber=0, likeNumber=44, createdTime=2021-05-19, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79120251eaf, moduleTitle=JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79120251eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080161, encodeId=0b86208016164, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析, objectType=article, longId=200657, objectId=46a120065e1f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46a120065e1f, replyNumber=0, likeNumber=30, createdTime=2021-08-25, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46a120065e1f, moduleTitle=Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46a120065e1f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080159, encodeId=96ae2080159e9, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, objectType=article, longId=191239, objectId=94ff191239b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94ff191239b4, replyNumber=0, likeNumber=36, createdTime=2020-06-29, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94ff191239b4, moduleTitle=拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94ff191239b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080163, encodeId=d891208016345, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=203137, objectId=f21a20313e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21a20313e8c, replyNumber=0, likeNumber=42, createdTime=2021-02-06, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21a20313e8c, moduleTitle=NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21a20313e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080158, encodeId=7fb22080158ca, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, objectType=article, longId=190970, objectId=6cd81909e0c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cd81909e0c0, replyNumber=0, likeNumber=63, createdTime=2020-04-26, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cd81909e0c0, moduleTitle=一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cd81909e0c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2080157, encodeId=d8c6208015e86, content=<a href='/topic/show?id=fc8c9969495' target=_blank style='color:#2F92EE;'>#非转移性#</a>, objectTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, objectType=article, longId=183719, objectId=f1bc183e1902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc183e1902, replyNumber=0, likeNumber=34, createdTime=2020-09-11, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc183e1902, moduleTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc183e1902)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非转移性

2020-05-29

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Radiology：CT+CA19-9的强强联手：非转移性胰腺癌的治疗反应评估

2023-04-03

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Radiology：CT和CA19-9对非转移性胰腺癌治疗效果的评估

2022-08-19

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Eur Urol：非转移性前列腺癌患者中，高强度聚焦超声局部治疗后的癌症控制结果

2022-12-08

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Front Oncol：非转移性非透明细胞肾细胞癌(non-ccRCC)患者的临床特征和临床预后差异

2022-02-10

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

BMC Cancer：随访长达10年的前瞻性研究证实女性非转移性乳腺癌患者越年轻预后越差

2022-03-19

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Eur Urol Focus：非转移性前列腺癌根治术后尿失禁的患者和肿瘤相关预后因素分析

2021-06-20

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

J Clin Oncol：长春新碱-拓扑替康-环磷酰胺用于非转移性尤文氏肉瘤初始治疗的III期临床试验结果

2022-05-26

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Prostate Cancer P D：非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较：倾向性评分匹配研究

2021-09-14

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Int J Urol：非转移性pT3a肾细胞癌的术后复发预测因素调查

2021-12-22

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

ASCO GU 2021: 达洛鲁胺治疗非转移性去势抵抗性前列腺癌疗效分析

2021-10-31

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

J Clin Oncol：放疗(RT)和雄激素剥夺疗法(ADT)联合或不联合多西他赛治疗非转移性的不良风险前列腺癌的疗效:一项前瞻性随机研究

2022-06-01

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量

2021-08-10

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？

2021-11-28

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！

2020-09-15

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

JAMA Oncology：一种新可以更好地预测非转移性前列腺癌患者预后的新分期系统

2021-05-19

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

Clin Cancer Res：阿帕他胺用于非转移性去势抵抗性前列腺癌的暴露-反应分析

2021-08-25

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

拜尔的雄激素受体拮抗剂Nubeqa在欧洲被授权，用于治疗非转移性前列腺癌

2020-06-29

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

NMPA批准XTANDI（恩杂鲁胺软胶囊）治疗非转移性去势抵抗性前列腺癌

2021-02-06

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

一例特殊非转移性去势抵抗性前列腺癌患者，个体化新型内分泌治疗后生存良好！

2020-04-26

yinhl1978 (审核中...)

前往app查看评论内容

#非转移性#

2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

2020-09-11

科室
- - 订阅+
  - 更多科室
工具
服务